Dr. Jason Hafron talks to OncLive about the costs of “false positive” results when screening for cancer

In a recent interview with OncLive, Dr. Jason Hafron of Michigan Institute of Urology addressed the significant financial and psychological burdens associated with false-positive results in cancer screening.

Beyond the initial diagnostic testing, false positives often trigger downstream costs, unnecessary follow-up procedures, and substantial anxiety for patients. Dr. Hafron highlights how advanced diagnostic tools, precision biomarker testing, and tailored risk assessments help clinicians minimize these errors, ensuring patients receive accurate results while avoiding unnecessary care.

Read the full article on OncLive to learn more about how modern diagnostic strategies are improving patient outcomes and reducing healthcare costs.